Ir J Med Sci (2017) 186:589–595 DOI 10.1007/s11845-017-1594-z ORIGINAL ARTICLE Transformed follicular lymphoma (tFL): consolidation therapy may improve survival 1,2 2,3 1,2 1,2 1,2 • • • • • E. Elhassadi R. Flavin P. Browne E. Conneally P. Hayden 4 1 1,2 • • F. Quinn E. Higgins E. Vandenberghe Received: 30 August 2016 / Accepted: 2 March 2017 / Published online: 21 March 2017 Royal Academy of Medicine in Ireland 2017 Abstract presented with stage III/IV disease. Thirteen (50%) patients Purpose Retrospective study to evaluate the outcome of presented with de novo tFL and the remainder had previ- patients with transformed follicular lymphoma (tFL) trea- ously diagnosed FL, with a median time to transformation ted with rituximab-containing chemotherapy and of 5.7 (range 1–15) years. The median follow-up time from consolidation. tFL diagnosis to December 2015 is 8 (range 4–14) years. Patients and methods Patients diagnosed with tFL from All patients received immuno-chemotherapy achieving an 2003 to 2013 treated with consolidation therapy with last overall response rate (ORR) of 100%. Fourteen (54%), follow-up in December 2015 were identiﬁed from the patients were transplant eligible and based on donor institutional lymphoma database and included in this study. availability, six had
Irish Journal of Medical Science (1971 -) – Springer Journals
Published: Mar 21, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud